Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Legend Biotech CorporationNASDAQ: LEGN

Retained Earnings · Q3 FY2026 · quarter ended Sep 2026

Retained earnings remains negative

Q3 FY2026 retained earnings was -$1.93B, compared with -$1.93B a year earlier.

Context

  • Retained earnings amounted to 114.7% of total assets at the end of Q3 FY2026, up 2.1 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.93B+2.6% QoQ
Last fiscal yearDec 2025
-$1.96B-17.9% YoY
Year agoSep 2025
-$1.93B-0.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year-17.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.96B) USD
Year-over-year change
-17.9%

Retained Earnings vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's Sep 2026 retained earnings of -$1.93B is the 9th highest of the 11 companies compared; the peer median is -$1.16B.
  • Its year-over-year change of -0.0% is the highest of 11, against a peer median of -12.3%.
  • Retained earnings amounts to 114.7% of total assets for LEGN, versus a peer median of 398.5%.
LEGN Competitors Peer median
Retained Earnings for LEGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLLSCellectis S.A.Mar 2026-$351.94M -1.2%—121.7%
DTILPrecision BioSciences, Inc.Mar 2026-$546.63M -8.7%—379.9%
CRBUCaribou Biosciences, Inc.Mar 2026-$621.6M -27.3%—417.2%
IPSCCentury Therapeutics, Inc.Mar 2026-$813.56M -15.3%—249.1%
RNACCartesian Therapeutics, Inc.Mar 2026-$861.56M -21.4%—298.7%
AUTLAutolus Therapeutics plcMar 2026-$1.46B -24.7%—276.7%
FATEFate Therapeutics, Inc.Mar 2026-$1.57B -9.0%—549.5%
LYELLyell Immunopharma, Inc.Mar 2026-$1.64B -17.6%—468.8%
LEGNLegend Biotech CorporationSep 2026-$1.93B -0.0%—114.7%
ATRAAtara Biotherapeutics, Inc.Mar 2026-$2.03B -0.5%—10131.6%
ALLOAllogene Therapeutics, Inc.Mar 2026-$2.05B -9.2%—518.6%
Peer median (excluding LEGN) -$1.16B-12.3%—398.5%

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents688.94M786.03M1.28B286.75M901.9M
Short-term Investments193.46M239.62M31M835.93M46.7M
Net Receivables58.55M44.52M157.06M124.89M250.3M
Inventory1.75M10.35M19.43M23.9M32M
Other Current Assets1.44M1.27M357K70K1.6M
Total Current Assets949.85M1.1B1.5B1.28B1.25B
Property, Plant & Equipment (Net)142.96M161.67M189.68M201.59M402M
Goodwill00000
Intangible Assets16.81M68.69M4.06M174.22M74.6M
Long-term Investments4.71M04.36M4.36M5M
Tax Assets00285K00
Other Non-current Assets5.15M1.49M152.42M6.06M5M
Total Non-current Assets169.62M231.84M350.81M386.24M486.6M
Total Assets1.12B1.33B1.85B1.67B1.73B
Account Payables7.04M31.69M20.16M37.19M81.2M
Short-term Debt0000319.1M
Tax Payables10M10.79M7.2M24.04M0
Deferred Revenue304K451K53.01M47.41M11.3M
Other Current Liabilities87.9M67M68K500K1M
Total Current Liabilities229.2M297.79M216.42M277.65M636.4M
Long-term Debt120.46M260.93M281.33M301.2M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.87M7.66M55.27M6.15M0
Other Non-current Liabilities396K233K56K(54K)8M
Total Non-current Liabilities124.32M288.86M380.82M351.96M95.2M
Total Liabilities353.52M586.65M597.24M629.61M731.6M
Common Stock31K33K36K37K100K
Retained Earnings(520.11M)(966.46M)(1.48B)(1.66B)(1.96B)
Accumulated OCI4.86M14.67M98.93M(68.16M)122.2M
Other Stockholders Equity19.7M39.05M074.43M88M
Minority Interest00000
Total Equity765.94M744.31M1.25B1.04B1B
Total Debt122.97M284.53M328.67M350.6M413.7M
Net Debt(565.97M)(501.5M)(949.04M)63.85M(488.2M)

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.